Documenta Ophthalmologica

, Volume 105, Issue 1, pp 41–49 | Cite as

Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis

  • Pantaleo Fornaro
  • Giovanni Calabria
  • Guido Corallo
  • Giovanni B. Picotti
Article

Abstract

Thioridazine and other antipsychotics (neuroleptics, dopaminergic antagonists) can cause degenerative retinopathies with histological, electrophysiological and symptomatological features similar to those of primary retinitis pigmentosa. It was formerly suggested that these retinopathies are due to drug absorption by melanin of the eye which damages the choriocapillaris first and subsequently the photoreceptors and the retinal pigment epithelium. An alternative explanation of the still unclear mechanisms involved in the pathogenesis of thioridazine and other phenothiazines retinopathies has underlined the role of the drug effects on the activity of some retinal enzymatic systems which can lead to retinal dystrophy. More recent data on the complex role of dopamine (DA) and of its receptor subtypes in the retina has provided evidence that the D2 family of DA receptors, in particular the D4 receptor, is involved in the control of the synthesis of melatonin, a factor that has been shown to regulate several aspects of retinal physiology and to increase photoreceptor susceptibility to be damaged by light. Based on this knowledge, as well as on clinical data and on pharmacological considerations concerning the differences recently shown to exist among the various antipsychotics as regards their affinity for the DA receptor subtypes, we hypothesize that neuroleptic induced blockade of retinal D2/D4 receptors is among the initial events of these drug-induced degenerative retinopathies. Clinicians should be aware of the retinotoxic effects not only of thioridazine and some others phenothiazines, but also of those possibly caused by other typical and atypical antipsychotics. By evaluating the retinal status and function before and during the treatment of psychiatric patients, it should be possible to choose more accurately the safest drugs, particularly when treating predisposed subjects.

antipsychotics dopamine retinal receptors retinopathy thioridazine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Inove F. Adverse reactions of antipsychotic drugs. Drug Intell Clin Pharm 1979; 13: 198–208.Google Scholar
  2. 2.
    Oshika T. Ocular adverse effects of neuropsychiatric agents. Incidence and management. Drug Saf 1995; 12(4): 256–63.Google Scholar
  3. 3.
    Wettherholm DH, Snow HL, Winter FC. A clinical study of pigmentary change in cornea and lens in chronic Chlorpromazine therapy. Arch Ophthamol 1965; 55–6.Google Scholar
  4. 4.
    Cameron ME. Skin and eye changes associated with Chlorpromazine therapy. Med J Aust 1966; 1: 478–80.Google Scholar
  5. 5.
    Siddal JR. Ocular toxic changes associated with Chlorpromazine and Thioridazine. Can J Ophtalmol 1966; 1: 190–8.Google Scholar
  6. 6.
    Mathalone MBR. Eye and skin changes in psychiatric patients treated with Chlorpromazine. Br J Ophthalmol 1967; 51: 86–93.Google Scholar
  7. 7.
    Reboton J Jr., Weak Ley RD, Bylenga ND, et al. Pigmentary retinopathy and iridocycloplegia in psychiatric patients. J Neuropsychiatry 1962; 3: 311–6.Google Scholar
  8. 8.
    Kinross-Right WJ. Newer phenothiazine drugs in treatment of nervous disorders. J Am Med Assoc 1959; 170: 1283–8.Google Scholar
  9. 9.
    Weekley RD, Potts AM, Reboton J, May RH. Pigmentary retinopathy in patients receiving high doses of a new phenothiazine. Arch Ophthalmol 1960; 64: 95–106.Google Scholar
  10. 10.
    Scott AW. Retinal pigmentation in a patients receiving Thioridazine. Arch Ophthalmol 1963; 70: 775–8.Google Scholar
  11. 11.
    Cameron ME, Lawrence JM, Olrich JC. Thioridazine (Mellaril) retinopathy. Br J Ophthalmol 1972; 56: 131–4.Google Scholar
  12. 12.
    Davidorf FH. Thioridazine pigmentary retinopathy. Arch Ophthalmol 1973; 90: 251–5.Google Scholar
  13. 13.
    Siddal JR. Ocular complications related to phenothiazines. Dis Nerv Syst 1968; 29(suppl.): 10–3.Google Scholar
  14. 14.
    Potts AM. Drug induced macular disease. Ophthalmol 1960; 70: 1054–7.Google Scholar
  15. 15.
    Hagopian V. Pigmentary retinopathy due to Thioridazine or Mellaril. Kresge Eye Inst Bull 1966; 10: 33–9.Google Scholar
  16. 16.
    Hamilton JD. Thioridazine retinopathy within the upper dosage limit. Psychosomatics 1985; 26(10): 823–4.Google Scholar
  17. 17.
    Lam RW, Remick RA. Pigmentary retinopathy associated with low dose Thioridazine treatment (Letter). Can Med Assoc J 1985; 132(7): 737.Google Scholar
  18. 18.
    Connell MM, Poley BJ, Mc Farlane JR. Chorioretinopathy associated with Thioridazine therapy. Arch Ophthalmol 1964; 71: 816–21.Google Scholar
  19. 19.
    Marmor MF. Is Thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. Br J Ophthalmol 1990; 74: 739–42.Google Scholar
  20. 20.
    Leinfelder PJ, Burian HM. Mellaril intoxication of retina with full restitution of function. Invest Ophthalmol Vis Sci 1964; 3: 466.Google Scholar
  21. 21.
    Potts AM. The concentration of phenothiazines in the eye of experimental animals. Invest Ophthalmol Vis Sci 1962; 1: 522–30.Google Scholar
  22. 22.
    Bonnie AN. Progression of Thioridazine induced retinopathy. Brattleboro Retreat Psychiatry Rev 1992 (June).Google Scholar
  23. 23.
    Bond WS, Yee SC. Ocular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm 1980; 37: 74–8.Google Scholar
  24. 24.
    Fornaro P, Placidi GF, Cavallacci G, Perossini M & Castrogiovanni P. L'elettroretinografia come possibile metodo di studio nell'attività dopaminergica nell'uomo. Riv Psichiatria 1980a; 1: 115–8.Google Scholar
  25. 25.
    Fornaro P, Castrogiovanni P, Perossini M Placidi GF, Cavallacci G. Electroretinography (ERG) as a tool of investigation in human psychopharmacology. Electroretinographic changes induced by a combination of Levo-DOPA and Carbi-DOPA. Acta Neurol 1980; 4: 293–9.Google Scholar
  26. 26.
    Perossini M, Fornaro P, Wirth A. Recent advances on the origin and modulation of the b-wave of the electroretinogram. Atti Fond Giorgio Ronchi 1982; 37: 27–33.Google Scholar
  27. 27.
    Fornaro P, Castrogiovanni P, Dell'Osso L, Perossini M, Placidi GF, Tassi G. Electroretinography (ERG) as a tool of investigation on dopaminergic activity in man. ERG changes induced by Perphenazine and Bromocriptine. Res Commun Psychol Psychiatr Behav 1984; 9: 307–23.Google Scholar
  28. 28.
    Bartel P, Blom M, Robinson E, Van der Meiden C, Sommers D, Becker P. The effects of levodopa and haloperidol on flash and pattern ERG and VEPs in normal humans. Doc Opthalmol 1990; 76: 55–64.Google Scholar
  29. 29.
    Perossini M, Fornaro P. Electroretinographic effects induced in humans by psychopharmacological agents. Doc Opthalmol 1990; 75: 1–9.Google Scholar
  30. 30.
    Hanitzch R, Lichtenberger T. The origin of b-wave and slow potentials in the mammalian ERG. Int Soc Clin Electrofisiol Vis (ISCEV) 39th Congress, Naples, Italy; July, 1996; 26–9.Google Scholar
  31. 31.
    Zawilska JB, Derbiszewska T, Nowak JZ. Clozapine and other neuroleptic drugs antagonize the light-evoked suppression of melatonin biosynthesis in chick retina: involvement of the D4 dopamine receptor. J Neural Transm 1994; 97: 107–7.Google Scholar
  32. 32.
    Nguyen-Legros J, Chanut E, Versaux-Botteri C, Simon A, Trouvin JH. Dopamine inhibits melatonin synthesis in photoreceptor cells through a D2-like receptor subtype in the rat retina: Biochemical and histochemical evidence. J Neurochem 1996; 67: 2514–20.Google Scholar
  33. 33.
    Zawilska JB, Nowak JZ. Dopamine D4-like receptors in vertebrate retina: does the retina offer a model for the D4 receptors analysis? Pol J Pharmacol 1997; 49: 201–11.Google Scholar
  34. 34.
    Tosini G, Dirden JC. Dopamine inhibits melatonin release in the mammalian retina: in vitro evidence. Neurosci Lett 2000; 286: 119–22.Google Scholar
  35. 35.
    Miller FS, Bunt-Milam AH, Kalina RE. Clinical ultrastructural study of Thioridazine retinopathy. Ophthalmology 1982; 89: 1478–88.Google Scholar
  36. 36.
    Kramer SG. Dopamine: a retinal neurotransmitter. I. Retinal uptake, storage and lightstimulated release of 3H-Dopamine in the retina in vivo. Invest Opthalmol 1971; 10: 438–52.Google Scholar
  37. 37.
    Zarbin MA, Wamslay JK, Palacios JM, Kuhar M. Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the cat, monkey and human retina. Brain Res 1986; 374: 75–92.Google Scholar
  38. 38.
    Cohen AI, Todd RD, Harmon S, O'Malley KL. Photoreceptors of mouse retinal possess D4 receptors coupled to adenylate cyclase. Proc Natl Acad Sci USA 1992; 89: 12093–7.Google Scholar
  39. 39.
    Tran VT, Dickman M. Differential localization of Dopamine D1 and D2 receptors in rat retina. Invest Opthalmol Vis Sci 1992; 33: 1620–6.Google Scholar
  40. 40.
    Dearry A, Burnside B. Dopaminergic regulation of cone retinomotor movements in isolated teleost retina. I. Induction of cone contraction is mediated by D2 receptors. J Neurochem 1986; 46: 1006–21.Google Scholar
  41. 41.
    Filip V, Balik J. Possible indication of dopaminergic blockade in man by electroretinography. Int Pharmacopsychiatry 1978; 13: 151–6.Google Scholar
  42. 42.
    Zinn KM, Marmor MF. Toxicology of the human retinal pigment epithelium. In: Zinn KM, Marmor MF, eds. The retinal pigment epithelium. Cambridge, MA: Harvard University Press, 1979; 395–412.Google Scholar
  43. 43.
    Botermans CHG. Primary pigmentary degeneration and its association with neurological diseases. In: Vinken PJ, Bruyn GW, eds. Neuroretinal degenerations. Amsterdam: North-Holland, 1972; 148–340.Google Scholar
  44. 44.
    Matsumoto M, Midaka K, Tada S, Tasaki Y, Yamaguchi J. Full length DNA and distribution of human dopamine D4 receptor. Mol Brain Res 1995; 29: 157–62.Google Scholar
  45. 45.
    Hawlina M, Ikeda H. Chronic treatment with Dopamine D2-agonist Bromocriptine prolongs functional survival of dystrophic RCS rat retinas. Int Soc Clin Electrophysiol Vis (ISCEV) 32th Symposium (abstract) Athens, Greece. June 1995; 26–9.Google Scholar
  46. 46.
    Nowak JZ, Kazula A, Golembiowska K. Melatonin increases serotonin-N-acetyltransferase activity and decreases dopamine synthesis in light-exposed chick retina: in vivo evidence supporting melatonin-dopamine interaction in retina. J Neurochem 1992; 59: 1499–502.Google Scholar
  47. 47.
    Cheze G, Ali MA. Rôle de l'epiphyse dans la migration du pigment epithelial retinien chez quelques teleosteens. Can J Zool 1976; 54: 475–81.Google Scholar
  48. 48.
    Pang SF, Yew DT. Pigment aggregation by melatonin in the retinal pigment epithelium and choroids of guinea pigs ‘Cavia porcellus’. Experientia 1979; 35: 231–3.Google Scholar
  49. 49.
    Pierce ME, Besharse JC. Circadian regulation of retinomotor movements. Interaction of melatonin and dopamine in the control of cone length. J Gen Physiol 1985; 86: 671–89.Google Scholar
  50. 50.
    Bersharse JC, Dunis DA. Rod photoreceptor disc shedding in eye cups: relationship to bicarbonate and aminoacids. Exp Eye Res 1983; 36: 567–80.Google Scholar
  51. 51.
    Weichman AF, O'steen WK. Melatonin increases photoreceptor susceptibility to light damage. Invest Opthalmol Vis Sci 1992; 33: 1894–902.Google Scholar
  52. 52.
    Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15: 265–70.Google Scholar
  53. 53.
    Sugawara T, Sieving PA, Iuvone PA, Bush R. The melatonin antagonist Luzindole protects retinal photoreceptors from light damage in the rat. Invest Opthalmol Vis Sci 1998; 12: 2458–65.Google Scholar
  54. 54.
    Wise JPH, Lorscheider FL. Low retinal dopamine and serum prolactin levels indicate an inherited dopaminergic abnormality in BW rats. Exp Eye Res 1981; 32: 541–51.Google Scholar
  55. 55.
    Shibasaki H, Kato M, Inomata H, Nishimura M, Arakawa T, Kobayashi T, Nagara H, Kuroiwa Y. Pigmentary degeneration of the retina in heredodegenerative neurological diseases. Acta Neurol Scand 1979; 59: 331–42.Google Scholar
  56. 56.
    Ellis CJK, Allen TGJ, Marsden CD, Ikeda H. Electroretinographic abnormalities in idiopathic Parkinson's disease and the effect of levodopa administration. Clin Vis Sci 1987; 1: 347–55.Google Scholar
  57. 57.
    Brunello N. Meccanismi molecolari nell'azione dei nuovi farmaci antipsicotici. Quaderni Psichiatr 1999; 3: 15–23.Google Scholar
  58. 58.
    Cervetto L, Demontis GC, Giannaccini G, Longoni BM, Macchia B, Macchia R, Martinelli A, Orlandini E. N-n-Propyl-substituted 3-(dimethylphenyl) piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and receptor binding studies. J Med Chem 1998; 41: 4933–8.Google Scholar
  59. 59.
    Djamgoz MBA, Hankins MW, Hirano J, Archer R. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997; 24: 3509–29.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Pantaleo Fornaro
    • 1
  • Giovanni Calabria
    • 2
  • Guido Corallo
    • 2
  • Giovanni B. Picotti
    • 1
  1. 1.Department of Psychiatric Sciences, Psychopharmacology SectionUniversity of GenoaItaly
  2. 2.Department of Neurological and Visual Sciences, Ophthalmology RUniversity of GenoaGenoaItaly

Personalised recommendations